{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-025382","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.272445+00:00","generated_at":"2026-06-01T00:55:50.199045+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GT Biopharma receives FDA clearance for IND of GTB-3650; Phase 1 trial to start H2 2024","bullets":["FDA cleared IND for GTB-3650, an NK cell engager for CD33+ leukemias; Phase 1 trial initiation expected H2 2024.","Initial Phase 1 clinical data for GTB-3650 expected in H1 2025.","GTB-5550 IND submission (B7H3 solid tumors) expected Q1 2025; basket trial in six solid tumor types planned for 2025.","Company becomes fully remote effective July 1, 2024; stockholder communications to San Francisco address.","Cash runway expected to fund operations into 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-025382","json":"https://secwatch.observer/filing/0001493152-24-025382.json","markdown":"https://secwatch.observer/filing/0001493152-24-025382.md","text":"https://secwatch.observer/filing/0001493152-24-025382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315224025382/0001493152-24-025382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315224025382/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:55:50.199045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}